The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Folic Acid, Pyridoxine, and Cyanocobalamin Combination Treatment and Age-Related Macular Degeneration in Women: The Women's Antioxidant and Folic Acid Cardiovascular Study
Open accessAbstract
BACKGROUND: Observational epidemiologic studies indicate a direct association between homocysteine concentration in the blood and the risk of age-related macular degeneration (AMD), but randomized trial data to examine the effect of therapy to lower homocysteine levels in AMD are lacking. Our objective was to examine the incidence of AMD in a trial of combined folic acid, pyridoxine hydrochloride (vitamin B(6)), and cyanocobalamin (vitamin B(12)) therapy. METHODS: We conducted a randomized, double-blind, placebo-controlled trial including 5442 female health care professionals 40 years or older with preexisting cardiovascular disease or 3 or more cardiovascular disease risk factors. A total of 5205 of these women did not have a diagnosis of AMD at baseline and were included in this analysis. Participants were randomly assigned to receive a combination of folic acid (2.5 mg/d), pyridoxine hydrochloride (50 mg/d), and cyanocobalamin (1 mg/d) or placebo. Our main outcome measures included total AMD, defined as a self-report documented by medical record evidence of an initial diagnosis after randomization, and visually significant AMD, defined as confirmed incident AMD with visual acuity of 20/30 or worse attributable to this condition. RESULTS: After an average of 7.3 years of treatment and follow-up, there were 55 cases of AMD in the combination treatment group and 82 in the placebo group (relative risk, 0.66; 95% confidence interval, 0.47-0.93 [P = .02]). For visually significant AMD, there were 26 cases in the combination treatment group and 44 in the placebo group (relative risk, 0.59; 95% confidence interval, 0.36-0.95 [P = .03]). CONCLUSIONS: These randomized trial data from a large cohort of women at high risk of cardiovascular disease indicate that daily supplementation with folic acid, pyridoxine, and cyanocobalamin may reduce the risk of AMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Homocysteine and Cardiovascular Disease
Refsum, H., Ueland, P. M., Nygård, O., & Vollset, S. E. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.31 · Cited by 2,180
Homocysteine and Risk of Ischemic Heart Disease and Stroke: A Meta-analysis
Homocysteine Studies Collaboration (2002) · JAMA · doi:10.1001/jama.288.16.2015 · Cited by 2,059
Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa060900 · Cited by 1,729
Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction
Bønaa, K. H., Njølstad, I., Ueland, P. M., Schirmer, H., Tverdal, A., Steigen, T., Wang, H., Nordrehaug, J. E., Arnesen, E., & Rasmussen, K. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055227 · Cited by 1,442
(2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)00967-9 · Cited by 814
A prospective study of cigarette smoking and age-related macular degeneration in women
Seddon, J. M. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540140029022 · Cited by 435
Folate Therapy and In-Stent Restenosis after Coronary Stenting
Lange, H., Suryapranata, H., De Luca, G., Börner, C., Dille, J., Kallmayer, K., Pasalary, M. N., Scherer, E., & Dambrink, J.-H. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032845 · Cited by 336
A Prospective Study of Cigarette Smoking and Risk of Age-Related Macular Degeneration in Men
Christen, W. G. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540140035023 · Cited by 320
Self-citation(1993) · Archives of Ophthalmology · doi:10.1001/archopht.1993.01090090052019 · Cited by 303
Biomarkers of Cardiovascular Disease as Risk Factors for Age-Related Macular Degeneration
Vine, A. K., Stader, J., Branham, K., Musch, D. C., & Swaroop, A. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.07.004 · Cited by 160
Cited by
Vitamin B12 in Health and Disease
O’Leary, F., & Samman, S. (2010) · Nutrients · doi:10.3390/nu2030299 · Cited by 524
Cholesterol in the retina: The best is yet to come
Pikuleva, I. A., & Curcio, C. A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.03.002 · Cited by 281
Causes of hyperhomocysteinemia and its pathological significance
Kim, J., Kim, H., Roh, H., & Kwon, Y. (2018) · Archives of Pharmacal Research · doi:10.1007/s12272-018-1016-4 · Cited by 276
Homocysteine – from disease biomarker to disease prevention
Smith, A. D., & Refsum, H. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13279 · Cited by 261
Metadata
- Authors
- Christen, W. G., Glynn, R. J., Chew, E. Y., Albert, C. M., & Manson, J. E.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2009-02-23
- Volume
- 169
- Issue
- 4
- Pages
- 335
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2062407374
- Cited by
- 180
- References
- 13
- FWCI
- 11.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.